Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission

Patients (pts) with newly diagnosed sAML may have previously received HMA therapy for an antecedent hematologic malignancy (eg, myelodysplastic syndrome [MDS]). Outcomes for pts with MDS who progress following HMA therapy are typically poor, with remission rates

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Tara Lin, Daniel H. Ryan, Ellen K. Ritchie, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Jonathan E. Kolitz, Gary J. Schiller, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes Tags: 137 Source Type: research